107 related articles for article (PubMed ID: 12145998)
1. [A case-control study of prevention of irinotecan-induced diarrhea: the reducing side effects of irinotecan by oral alkalization combined with control of defecation].
Takeda Y; Kobayashi K; Akiyama Y; Soma T; Handa S; Kudoh S; Kudo K
Gan To Kagaku Ryoho; 2002 Jul; 29(7):1171-7. PubMed ID: 12145998
[TBL] [Abstract][Full Text] [Related]
2. Prevention of irinotecan (CPT-11)-induced diarrhea by oral alkalization combined with control of defecation in cancer patients.
Takeda Y; Kobayashi K; Akiyama Y; Soma T; Handa S; Kudoh S; Kudo K
Int J Cancer; 2001 Apr; 92(2):269-75. PubMed ID: 11291056
[TBL] [Abstract][Full Text] [Related]
3. A phase I/II trial of irinotecan-cisplatin combined with an anti-late-diarrhoeal programme to evaluate the safety and antitumour response of this combination therapy in patients with advanced non-small-cell lung cancer.
Takeda Y; Tsuduki E; Izumi S; Hojo M; Kamimura M; Naka G; Kobayashi K; Kudo K
Br J Cancer; 2005 Dec; 93(12):1341-9. PubMed ID: 16288302
[TBL] [Abstract][Full Text] [Related]
4. Prevention of irinotecan-induced diarrhea by oral sodium bicarbonate and influence on pharmacokinetics.
Tamura T; Yasutake K; Nishisaki H; Nakashima T; Horita K; Hirohata S; Ishii A; Hamano K; Aoyama N; Shirasaka D; Kamigaki T; Kasuga M
Oncology; 2004; 67(5-6):327-37. PubMed ID: 15713987
[TBL] [Abstract][Full Text] [Related]
5. Irinotecan-induced neutropenia is reduced by oral alkalization drugs: analysis using retrospective chart reviews and the spontaneous reporting database.
Hamano H; Mitsui M; Zamami Y; Takechi K; Nimura T; Okada N; Fukushima K; Imanishi M; Chuma M; Horinouchi Y; Izawa-Ishizawa Y; Kirino Y; Nakamura T; Teraoka K; Ikeda Y; Fujino H; Yanagawa H; Tamaki T; Ishizawa K
Support Care Cancer; 2019 Mar; 27(3):849-856. PubMed ID: 30062585
[TBL] [Abstract][Full Text] [Related]
6. Weekly administration of irinotecan (CPT-11) plus cisplatin for refractory or relapsed small cell lung cancer.
Ando M; Kobayashi K; Yoshimura A; Kurimoto F; Seike M; Nara M; Moriyama G; Mizutani H; Hibino S; Gemma A; Okano T; Shibuya M; Kudoh S
Lung Cancer; 2004 Apr; 44(1):121-7. PubMed ID: 15013590
[TBL] [Abstract][Full Text] [Related]
7. Prevention of irinotecan-induced diarrhoea by oral carbonaceous adsorbent (Kremezin) in cancer patients.
Maeda Y; Ohune T; Nakamura M; Yamasaki M; Kiribayashi Y; Murakami T
Oncol Rep; 2004 Sep; 12(3):581-5. PubMed ID: 15289841
[TBL] [Abstract][Full Text] [Related]
8. Preventive effect of Kampo medicine (Hangeshashin-to) against irinotecan-induced diarrhea in advanced non-small-cell lung cancer.
Mori K; Kondo T; Kamiyama Y; Kano Y; Tominaga K
Cancer Chemother Pharmacol; 2003 May; 51(5):403-6. PubMed ID: 12687289
[TBL] [Abstract][Full Text] [Related]
9. Prevention of irinotecan associated diarrhea by intestinal alkalization. A pilot study in gastrointestinal cancer patients.
Valentí Moreno V; Brunet Vidal J; Manzano Alemany H; Salud Salvia A; Llobera Serentill M; Cabezas Montero I; Servitja Tormo S; Sopena Bert E; Gumà Padró J
Clin Transl Oncol; 2006 Mar; 8(3):208-12. PubMed ID: 16648121
[TBL] [Abstract][Full Text] [Related]
10. Intestinal alkalization as a possible preventive mechanism in irinotecan (CPT-11)-induced diarrhea.
Ikegami T; Ha L; Arimori K; Latham P; Kobayashi K; Ceryak S; Matsuzaki Y; Bouscarel B
Cancer Res; 2002 Jan; 62(1):179-87. PubMed ID: 11782376
[TBL] [Abstract][Full Text] [Related]
11. [Kampo medicines for the prevention of irinotecan-induced diarrhea in advanced non-small cell lung cancer].
Mori K; Hirose T; Machida S; Tominaga K
Gan To Kagaku Ryoho; 1998 Jul; 25(8):1159-63. PubMed ID: 9679578
[TBL] [Abstract][Full Text] [Related]
12. Phase I pharmacokinetic, food effect, and pharmacogenetic study of oral irinotecan given as semisolid matrix capsules in patients with solid tumors.
Soepenberg O; Dumez H; Verweij J; de Jong FA; de Jonge MJ; Thomas J; Eskens FA; van Schaik RH; Selleslach J; Ter Steeg J; Lefebvre P; Assadourian S; Sanderink GJ; Sparreboom A; van Oosterom AT
Clin Cancer Res; 2005 Feb; 11(4):1504-11. PubMed ID: 15746053
[TBL] [Abstract][Full Text] [Related]
13. Phase II study of activated charcoal to prevent irinotecan-induced diarrhea.
Michael M; Brittain M; Nagai J; Feld R; Hedley D; Oza A; Siu L; Moore MJ
J Clin Oncol; 2004 Nov; 22(21):4410-7. PubMed ID: 15514383
[TBL] [Abstract][Full Text] [Related]
14. Phase I clinical trial of irinotecan (CPT-11), 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxy-camptothecin, and cisplatin in combination with fixed dose of vindesine in advanced non-small cell lung cancer.
Shinkai T; Arioka H; Kunikane H; Eguchi K; Sasaki Y; Tamura T; Ohe Y; Oshita F; Nishio M; Karato A
Cancer Res; 1994 May; 54(10):2636-42. PubMed ID: 8168091
[TBL] [Abstract][Full Text] [Related]
15. Cefixime allows greater dose escalation of oral irinotecan: a phase I study in pediatric patients with refractory solid tumors.
Furman WL; Crews KR; Billups C; Wu J; Gajjar AJ; Daw NC; Patrick CC; Rodriguez-Galindo C; Stewart CF; Dome JS; Panetta JC; Houghton PJ; Santana VM
J Clin Oncol; 2006 Feb; 24(4):563-70. PubMed ID: 16446328
[TBL] [Abstract][Full Text] [Related]
16. Prophylaxis of irinotecan-induced diarrhea with neomycin and potential role for UGT1A1*28 genotype screening: a double-blind, randomized, placebo-controlled study.
de Jong FA; Kehrer DF; Mathijssen RH; Creemers GJ; de Bruijn P; van Schaik RH; Planting AS; van der Gaast A; Eskens FA; Janssen JT; Ruit JB; Verweij J; Sparreboom A; de Jonge MJ
Oncologist; 2006 Sep; 11(8):944-54. PubMed ID: 16951398
[TBL] [Abstract][Full Text] [Related]
17. A phase I study of irinotecan and infusional cisplatin for advanced non-small-cell lung cancer.
Mori K; Ohnishi T; Yokoyama K; Tominaga K
Cancer Chemother Pharmacol; 1997; 39(4):327-32. PubMed ID: 9025773
[TBL] [Abstract][Full Text] [Related]
18. [Preventive effect of TJ-14, a kampo (Chinese herb) medicine, on diarrhea induced by irinotecan hydrochloride (CPT-11)].
Sakata Y; Suzuki H; Kamataki T
Gan To Kagaku Ryoho; 1994 Jul; 21(8):1241-4. PubMed ID: 8031168
[TBL] [Abstract][Full Text] [Related]
19. Post-marketing surveillance (PMS) of all patients treated with irinotecan in Japan: clinical experience and ADR profile of 13,935 patients.
Tadokoro J; Kakihata K; Shimazaki M; Shiozawa T; Masatani S; Yamaguchi F; Sakata Y; Ariyoshi Y; Fukuoka M
Jpn J Clin Oncol; 2011 Sep; 41(9):1101-11. PubMed ID: 21852251
[TBL] [Abstract][Full Text] [Related]
20. Randomized comparison of prophylactic antidiarrheal treatment versus no prophylactic antidiarrheal treatment in patients receiving CPT-11 (irinotecan) for advanced 5-FU-resistant colorectal cancer: an open-label multicenter phase II study.
Ychou M; Douillard JY; Rougier P; Adenis A; Mousseau M; Dufour P; Wendling JL; Burki F; Mignard D; Marty M
Am J Clin Oncol; 2000 Apr; 23(2):143-8. PubMed ID: 10776974
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
